We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug
Read MoreHide Full Article
Clovis Oncology, Inc. announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has issued a positive opinion recommending approval of PARP inhibitor, Rubraca (rucaparib). The company is seeking approval of the drug as monotherapy for the treatment of women with platinum-sensitive ovarian cancer with BRCA mutation.
Clovis expects a final decision from the EMA in the second quarter of 2018.
Rubraca is already approved in the United States for this indication.
Clovis’ shares have lost 15.8% so far this year, underperforming the industry’s decline of 5.9% in that period.
The CHMP nod was based on positive objective response rate and duration of response data from two clinical studies, Study 10 and ARIEL 2, evaluating Rubraca in patients whose disease has progressed after two or more chemotherapies.
Following the potential approval of Rubraca in Europe, Clovis is planning to file a variation to the marketing application seeking approval in a broader maintenance indication. The application will include significantly improved progression free survival data from ARIEL 3 study. A similar application in under review in the United States.
Concurrently, Clovis also initiated an early access program for Rubraca in Europe as a treatment and maintenance therapy for recurrent ovarian cancer
Per the press release, a quarter of 65,000 patients diagnosed with ovarian cancer annually have BRCA mutation. The patients have limited treatment options available, which represents significant unmet need.
However, Clovis’ Rubraca will face competition from other PARP inhibitors including Tesaro, Inc.'s Zejula and AstraZeneca's (AZN - Free Report) Lynparza as both these drugs are already approved to treat ovarian cancer in the EU. The drugs also enjoy advantage over Rubraca as they are approved in patients irrespective of the BRCA-mutation.
Meanwhile, a phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
Horizon Pharma’s earnings estimates increased from $1.30 to $1.43 for 2018 and from $1.54 to $1.77 for 2019 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 68.92%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug
Clovis Oncology, Inc. announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has issued a positive opinion recommending approval of PARP inhibitor, Rubraca (rucaparib). The company is seeking approval of the drug as monotherapy for the treatment of women with platinum-sensitive ovarian cancer with BRCA mutation.
Clovis expects a final decision from the EMA in the second quarter of 2018.
Rubraca is already approved in the United States for this indication.
Clovis’ shares have lost 15.8% so far this year, underperforming the industry’s decline of 5.9% in that period.
The CHMP nod was based on positive objective response rate and duration of response data from two clinical studies, Study 10 and ARIEL 2, evaluating Rubraca in patients whose disease has progressed after two or more chemotherapies.
Following the potential approval of Rubraca in Europe, Clovis is planning to file a variation to the marketing application seeking approval in a broader maintenance indication. The application will include significantly improved progression free survival data from ARIEL 3 study. A similar application in under review in the United States.
Concurrently, Clovis also initiated an early access program for Rubraca in Europe as a treatment and maintenance therapy for recurrent ovarian cancer
Per the press release, a quarter of 65,000 patients diagnosed with ovarian cancer annually have BRCA mutation. The patients have limited treatment options available, which represents significant unmet need.
However, Clovis’ Rubraca will face competition from other PARP inhibitors including Tesaro, Inc.'s Zejula and AstraZeneca's (AZN - Free Report) Lynparza as both these drugs are already approved to treat ovarian cancer in the EU. The drugs also enjoy advantage over Rubraca as they are approved in patients irrespective of the BRCA-mutation.
Meanwhile, a phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote
Zacks Rank & Stock to Consider
Clovis currently carries a Zacks Rank #4 (Sell).
Horizon Pharma Public Limited Company is a better-ranked stock in the health care space, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Horizon Pharma’s earnings estimates increased from $1.30 to $1.43 for 2018 and from $1.54 to $1.77 for 2019 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 68.92%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>